Trial · NCT02584608

Use of ACTIMMUNE in Patients With ADO2

NCT02584608, Phase 2, Completed, Indiana University; results first posted 2021-01-08

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Use of ACTIMMUNE in Patients With ADO2. Trials, record NCT02584608. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02584608

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Use of ACTIMMUNE in Patients With ADO2
NCT number: NCT02584608
Status: Completed
Phases: Phase 2
Enrollment: 12 participants, actual
Lead sponsor: Indiana University
Conditions: Autosomal Dominant Osteopetrosis Type 2
Interventions: ACTIMMUNE
First posted: 2015-10-22
Last updated: 2021-01-08
Results first posted: 2021-01-08

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Changes in Bone Resorption Markers From Baseline to 14 Weeks.	baseline, 14 weeks	Evaluate for changes in bone resorption markers including CTX, NTX/creatinine ratio between baseline and 14 weeks
Secondary	Change in Bone Turnover Markers Between After Completion of 6-12 Weeks of Treatment	6-12 weeks	Evaluate for changes in bone turnover markers including TRAP5b, NTX, CTX/TRAP5b ratio after 6-12 weeks of treatment.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Changes in Bone Resorption Markers From Baseline to 14 Weeks.	baseline, 14 weeks	All subjects	percentage of change	MEAN
SECONDARY	Change in Bone Turnover Markers Between After Completion of 6-12 Weeks of Treatment	6-12 weeks	all subjects	percentage of change	MEAN

Source ClinicalTrials.gov

Results by group5

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Changes in Bone Resorption Markers From Baseline to 14 Weeks.	Treatment	Percent change of CTX	2.2	Full Range -35.7 to 90.5	percentage of change
Changes in Bone Resorption Markers From Baseline to 14 Weeks.	Treatment	Percent change of NTX/creatinine ratio	-2.1	Full Range -50.5 to 55.5	percentage of change
Change in Bone Turnover Markers Between After Completion of 6-12 Weeks of Treatment	Treatment	TRAP5B	-15.34	Full Range -57.07 to 13.1	percentage of change
Change in Bone Turnover Markers Between After Completion of 6-12 Weeks of Treatment	Treatment	NTX	-2.09	Full Range -50.51 to 55.54	percentage of change
Change in Bone Turnover Markers Between After Completion of 6-12 Weeks of Treatment	Treatment	CTX/TRAP5b ratio	26.31	Full Range -35.91 to 144.57	percentage of change

Source ClinicalTrials.gov

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Treatment	12
Overall Study	COMPLETED	Treatment	12
Overall Study	NOT COMPLETED	Treatment	0

Source ClinicalTrials.gov

Adverse events25

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Headache	Nervous system disorders	Treatment	10	12
other	Fatigue	Nervous system disorders	Treatment	9	12
other	nausea	Gastrointestinal disorders	Treatment	9	12
other	flu like symptoms	Product Issues	Treatment	8	12
other	myalgia	Musculoskeletal and connective tissue disorders	Treatment	7	12
other	white blood cell decreased	Blood and lymphatic system disorders	Treatment	6	12
other	arthralgia	Musculoskeletal and connective tissue disorders	Treatment	5	12
other	diarrhea	Gastrointestinal disorders	Treatment	5	12
other	neutrophil count decreased	Blood and lymphatic system disorders	Treatment	5	12
other	vomiting	Gastrointestinal disorders	Treatment	5	12

1 to 10 of 25Source ClinicalTrials.gov

See all 25 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Treatment	0	12
Total, other adverse events	Treatment	10	12
Total, serious adverse events	Treatment	0	12

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
30889272	RESULT

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02584608

GET https://conductscience.org/api/trials/v1/NCT02584608/events?page=2

API reference For AI assistants